Mroczek 1991.

Methods	4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐114 mm Hg at each of last 2 visits during run‐in; 4‐week double‐blind treatment
Participants	Cilazapril 2.5 mg: n=59(45 males,14 females); mean age=52.4 years; baseline sitting SBP=146.3 mm Hg, DBP=101.1 mm Hg, HR=75.5 bpm; Cilazapril 5 mg: n=59(41 males,18 females); mean age=52.9 years; baseline sitting SBP=148.4 mm Hg, DBP=101.3 mm Hg, HR=76.2 bpm; Cilazapril 10 mg: n=58(34 males,24 females); mean age=50.3 years; baseline sitting SBP=144.3 mm Hg, DBP=100.8 mm Hg, HR=75.1 bpm; Placebo: n=59(36 males,23 females); mean age=54.0 years; baseline sitting SBP=149.8 mm Hg, DBP=100.7 mm Hg, HR=77.3 bpm
Interventions	Cilazapril 2.5 mg once daily; Cilazapril 5 mg once daily; Cilazapril 10 mg once daily; Placebo; taken in the morning after light breakfast
Outcomes	Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer; Mean change from baseline in trough sitting HR; WDAE
Notes	BP change and SE of change reported, endpoint BP and SE reported; calculated SD of change from N and SE of change; BP data from text and Table 2, p. 1424; Jadad score=3; funding source= not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear